HOUSTON - nvtip -- UK healthcare innovator, RD Biomed, developed Peptest, the world's first non-invasive test for reflux, in 2007.  Since that time it has grown to global prominence. Shipping costs and wait times were a barrier to the U.S. market preventing the adoption of this direct to consumer diagnostic test. Now with Restech managing the PepsinCheck operations, the test is shipped from the U.S., processed at strategically located American labs, and results are sent back to the consumer by mail and a secure email within about a week.

Both PepsinCheck (U.S. market) and Peptest (non-U.S. markets) are manufactured by RD Biomed to the same global standard. The test detects the presence of the stomach enzyme pepsin (recognized as a reliable diagnostic biomarker for reflux) in saliva and sputum samples.

Restech VP of Clinical Affairs, Thomas Ball, commented, "As we Rethink Reflux across the continuum of care, direct to consumer healthcare plays a pivotal role.  RD Biomed and the Peptest provide an ideal accompaniment to our product portfolio, ensuring that tough diagnostic cases find appropriate physician-based care in addition to broadening our reach to an unprecedented range of patients. PepsinCheck represents the first at-home reflux testing in the US market and holds the potential to revolutionize the care of individuals with symptoms ranging from heartburn, to chronic cough, and even obstructive sleep apnea."

More on nvtip.com

• ProSource Diesel,Where Repair Shops Shop for Hard-to-Find Truck Parts and Kits, Celebrates Anniversary!
• JD Merit Advises Apex Linen Service on Chapter 11 §363 Sale
• U.S. Gold Corp. Director Tara Gilfillan Named Among 100 Global Inspirational Women in Mining
• CEO Coaching International Congratulates Client CBC Federal Credit Union for Customer Service Accolades
• Desiccare, Inc. Desiccants Keeping COVID-19 Test Kits, Diagnostic Test Kits, and Pharmaceutical Products Safe and Effective

Professor Peter Dettmar, Director of RD Biomed, said: "We're thrilled that our salivary pepsin test for diagnosing reflux has officially launched in the US. It has been a pleasure working with Restech, a successful digestive health solutions company, and we could not have chosen a better company to distribute and commercialise PepsinCheck by Peptest."

About Restech

At Restech, we believe there is a better way to manage reflux. Our team designed and launched the first real-time sensor that could function highly accurately in a non-liquid environment. Since then, we've obsessed over reflux, developing and seeking out new products across the diagnostic and therapeutic continuum. www.restech.com

About RD Biomed & Peptest

RD Biomed is a pharmaceutical development and diagnostic company based at Castle Hill Hospital in Hull, East Yorkshire. Innovators in healthcare product development, RD Biomed focusses on gastroenterology and wound management and develops products that identify, prevent and treat various medical conditions.  www.peptest.co.uk

More on nvtip.com

• L2 Aviation receives FAA STC approval for Ka-band system installations on Boeing 767 aircraft
• Paul Bruno's The Original Jeeps⸺The Race To Build America's First Jeeps Now In Kindle Format
• Zippy Shell and Subsidiary 1-800-PACK-RAT Secure Financing from The Carlyle Group & PNC Bank
• Elf Prep Academy Trains Elf Recruits to Help Santa Spread Holiday Cheer Just in Time for Christmas
• Syxsense Announces New Support for Amazon Web Service (AWS) Linux Devices

CONTACTS

Thomas Ball
Vice President of Clinical Affairs
T: 1.800.352.1512
E: tball@restech.com

Harvey Dettmar
Director, RD Biomed Limited
T: +44 1482 461866
E: harvey.dettmar@technostics.com

www.pepsincheck.com